BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 7684863)

  • 1. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
    Bolger JJ; Dearnaley DP; Kirk D; Lewington VJ; Mason MD; Quilty PM; Reed NS; Russell JM; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):32-3. PubMed ID: 7684863
    [No Abstract]   [Full Text] [Related]  

  • 2. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
    Porter AT; McEwan AJ
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
    Kan MK
    Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 89Strontium in the management of painful sceletal metastases.
    Kälkner KM; Westlin JE; Strang P
    Anticancer Res; 2000; 20(2B):1109-14. PubMed ID: 10810404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [89-Strontium for painful osteoblastic metastases].
    Golan H; Ratz D
    Harefuah; 1995 May; 128(10):650-4. PubMed ID: 7541384
    [No Abstract]   [Full Text] [Related]  

  • 6. Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone.
    Porter AT
    Eur Urol; 1994; 26 Suppl 1():20-5. PubMed ID: 7537665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience.
    Lee CK; Aeppli DM; Unger J; Boudreau RJ; Levitt SH
    Am J Clin Oncol; 1996 Apr; 19(2):102-7. PubMed ID: 8610630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
    De Ruysscher D; Spaas P; Specenier P
    Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone.
    McEwan AJ; Amyotte GA; McGowan DG; MacGillivray JA; Porter AT
    Eur Urol; 1994; 26 Suppl 1():26-31. PubMed ID: 7537666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
    Hansen DV; Holmes ER; Catton G; Thorne DA; Chadwick DH; Schmutz DA
    Am Fam Physician; 1993 Jun; 47(8):1795-800. PubMed ID: 7684554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic radionuclide therapy of bone metastases with strontium-89.
    Porter AT; Davis LP
    Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
    Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Palliative pain relief treatment for multiple bone metastases by strontium-89].
    Nishio M
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():581-5. PubMed ID: 22208048
    [No Abstract]   [Full Text] [Related]  

  • 15. [Strontium-89 for bone metastases from prostate cancer: an update].
    Zhao WW; Xie P; Deng HF
    Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of repeated systematic radiotherapy for generalized prostate cancer].
    Kiselev EN; Korytova LI; Karelin MI
    Vopr Onkol; 2005; 51(6):689-91. PubMed ID: 17037036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
    Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M; Buchali K; Pink V; Lips H
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating symptomatic osseous metastases from prostate cancer.
    Soffen EM; Greenberg AS; Baumann JC
    N J Med; 1997 Nov; 94(11):33-7. PubMed ID: 9385818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.